In The Netherlands an excellent infrastructure exists for the performance of multicentre clinical studies in patients with colorectal cancer. Examples are the TME, PROCTOR/SCRIPT, and CAIRO studies. The success of these studies is largely due to the collaboration between the relevant disciplines, such as surgery, radiotherapy, medical oncology, and pathology, as well as the support from data centres such as the regional trial offices of the Comprehensive Cancer Centres. This allows the conduct of large randomized studies with objectives that are relevant to clinical practice in The Netherlands.
The Dutch Colorectal Cancer Group (DCCG) is a collaboration between medical disciplines that are relevant for the diagnosis and treatment of colorectal cancer (surgical oncology, radiotherapy, medical oncology, pathology, radiology, gastroenterology, genetics). The primary goal of the DCCG is to improve the quality of diagnosis and treatment of patients with colorectal cancer on a national level through the initiation of clinical scientific research.
The DCCG Foundation is registered at the Chamber of Commerce Centraal Gelderland by number 52113191. The DCCG Foundation is registered as ANBI (Algemeen Nut Beogende Instellingen).
New developments of the DCCG are communicated by newsletters and on the website, as well as during a conference that is held once a year. The DCCG organizes once every two years the European Multidisciplinary Colorectal Cancer Conference (EMCCC), please click here for more information.